Antiviral compounds

US9693997B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9693997-B2
Application numberUS-201414768915-A
CountryUS
Kind codeB2
Filing dateMar 3, 2014
Priority dateMar 6, 2013
Publication dateJul 4, 2017
Grant dateJul 4, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of formula I: wherein: A is phenyl, naphthyl, or bicyclic unsaturated or partially saturated heteroaryl, substituted with one or more A; each A is independently lower alkyl, halo, lower alkoxy, S(═O) 2 (CH 2 ) m A″, C(═O)NHA″, NHC(O)A″, —O(CH 2 ) m A″, (CHA 1 ) m NHS(═O) 2 A 1 ; or S(═O) 2 NHA″; each A″ is independently, heterocycloalkyl or heteroaryl, optionally substituted with one or more A′″; each A′″ is independently hydroxy, lower alkyl, oxo, C(═O)OA 1 , halo loweralkyl, each A 1 is independently H, lower alkyl, halo loweralkyl, amino, lower alkoxy, each m is independently 0, 1, 2, or 3; R 1 is H, halo, lower alkyl, halo loweralkyl, SF 5 , and R 2 is H, halo, lower alkyl, halo loweralkyl, or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein A is phenyl. 3. The compound of claim 2 , wherein R 1 is halo loweralkyl. 4. The compound of claim 3 , wherein R 2 is halo. 5. The compound of claim 2 , wherein R 1 is halo. 6. The compound of claim 5 , wherein R 2 is halo. 7. The compound of claim 1 , wherein A′ is S(═O) 2 (CH 2 ) m A″ or (CH 2 ) m S(═O) 2 A″. 8. The compound of claim 1 , wherein A′ is lower alkyl, halo, or lower alkoxy. 9. The compound of claim 1 , wherein A′ is C(═O)NHA″ or NHC(═O)A″. 10. The compound of claim 1 , wherein A′ is (CHA 1 ) m NHS(═O) 2 A 1 or S(═O) 2 NHA″. 11. The compound of claim 1 , wherein A′ is O(CH 2 ) m A″. 12. A compound selected from the group consisting of: 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-piperidine-1-carboxylic acid tert-butyl ester; 3-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonylmethyl]-piperidine-1-carboxylic acid tert-butyl ester; (S)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluormethyl-biphenyl-4-sulfonyl]-pyrrolidine-2-carboxylic acid tert-butyl ester; N 3 -{6-Chloro-2-trifluoromethyl-4′-[1-(3,3,3-trifluoro-propyl)-piperidine-4-sulfonyl]-biphenyl-4-yl}-1H-[1,2,4]triazole-3,5-diamine; N 3 -{6-Chloro-4′-[1-(3,3-dimethyl-butyl)-piperidine-4-sulfonyl]-2-trifluoromethyl-biphenyl-4-yl}-H-[1,2,4]triazole-3,5-diamine; 3-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-piperidine-1-carboxylic acid tert-butyl ester; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonylmethyl]-piperidine-1-carboxylic acid tert-butyl ester; 4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-carboxylic acid tert-butylamide; Pentanoic acid [4′-(5-amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yl]-amide; N 3 -[4-(2-tert-Butyl-1,1-dioxo-2,3-dihydro-1H-1λ 6 -benzo[d]isothiazol-6-yl)-3-chloro-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -{6-Chloro-2-trifluoromethyl-4′-[1-(3,3,3-trifluoro-propyl)-piperidine-3-sulfonyl]-biphenyl-4-yl}-1H-[1,2,4]triazole-3,5-diamine; N-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-ylmethyl]-methanesulfonamide; N—{(S)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-yl]-ethyl}-methanesulfonamide; N 3 -(2,6-Dichloro-4′-methanesulfonyl-3′-trifluoromethyl-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(1-methanesulfonyl-1H-indol-4-yl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-piperazine-1-carboxylic acid tert-butyl ester; N 3 -{6-Chloro-4′-[1-(3,3-dimethyl-butyl)-piperidine-3-sulfonyl]-2-trifluoromethyl-biphenyl-4-yl}-1H-[1,2,4]triazole-3,5-diamine; 4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-4-methyl-6′-trifluoromethyl-biphenyl-3-sulfonic acid tert-butylamide; N 3 -[2-Chloro-4′-methoxy-3′-(propane-2-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(piperidine-4-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-3-yloxy]-piperidine-1-carboxylic acid tert-butyl ester; N 3 -[2-Chloro-4′-(4-methyl-piperazine-1-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-6-fluoro-4′-(propane-2-sulfonyl)-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N—{(R)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-yl]-ethyl}-methanesulfonamide; N 3 -[2-Chloro-4′-(piperidin-3-ylmethanesulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yloxy]-butyronitrile; 4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonic acid ((S)-1-pyrolidin-2-ylmethyl)-amide; N-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-2-fluoro-biphenyl-4-yl]-methanesulfonamide; N 3 -[2-Chloro-4′-(piperidine-3-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -(2-Chloro-6-fluoro-4′-methanesulfonyl-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(2,6-Dichloro-4′-methanesufonylmethyl-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -[4′-(Azetidin-3-ylmethoxy)-2,6-dichloro-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(piperazine-1-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; 4′(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-fluoro-biphenyl-4-sulfonic acid dimethylamide; N 3 -[2-Chloro-4′-((S)-1-pyrrolidin-2-ylmethanesulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(morpholine-4-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[4′-(Azetidin-3-ylmethoxy)-2-chloro-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N-{2-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-yl]-ethyl}-methanesulfonamide; 5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid [4′-(5-amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yl]-amide; N 3 -[2-Chloro-4′-(piperidin-4-ylmethanesulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-3′-(piperidin-4-yloxy)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(1-methanesulfonyl-1H-indol-5-yl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; 1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yl]-pyrrolidin-2-one; N 3 -[3-Chloro-4-(4-methanesulfonyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(1,1-dioxo-1λ 6 -thiomorpholine-4-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-3-fluoro-biphenyl-4-yl]-methanesulfonamide; 6-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2-chloro-6-trifluoromethyl-phenyl]-4H-benzo[1,4]oxazin-3-one; N 3 -(2,6-Dichloro-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -[4′-(4-Amino-butoxy)-2,6-dichloro-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; compound with trifluoro-acetic acid; N 3 -(4′-Amino-2,6-dichloro-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; (S)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-pyrrolidine-2-carboxylic acid; N 3 -[3,5-Dichloro-4-(2,2-dimethyl-4,4-dioxo-3,4-dihydro-2H-4λ 6 -benzo[1,4]oxathiin-6-yl

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • for RNA viruses · CPC title

  • linked by a chain containing hetero atoms as chain links · CPC title

  • containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

  • linked by a chain containing hetero atoms as chain links · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9693997B2 cover?
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
Who is the assignee on this patent?
Hoffmann La Roche
What technology area does this patent fall under?
Primary CPC classification A61K31/4196. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).